TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 12/3030% below fair value
$1.82−0.03 (-1.62%)
Close on Nov 12, 2026Market cap $21.07MP/E –Yield –
TherapeuticsMD r&d expenses
Research and development expenses are spending on new products and technology.
TherapeuticsMD's R&D Expenses for the twelve months ending Sep 30, 2022 was $5.51M, down 31.6% year over year. For fiscal 2021 it was $7.09M, down 32.1% from the year before. Over ten years it grew 52.1% a year on average. The highest annual figure on record is $72.04M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $7.09M | -32.1% |
| FY2020 | Dec 31, 2020 | $10.43M | -47.3% |
| FY2019 | Dec 31, 2019 | $19.79M | -27.5% |
| FY2018 | Dec 31, 2018 | $27.30M | -19.4% |
| FY2017 | Dec 31, 2017 | $33.85M | -37.2% |
| FY2016 | Dec 31, 2016 | $53.94M | -25.1% |
| FY2015 | Dec 31, 2015 | $72.04M | +66.7% |
| FY2014 | Dec 31, 2014 | $43.22M | +218.9% |
| FY2013 | Dec 31, 2013 | $13.55M | +201.7% |
| FY2012 | Dec 31, 2012 | $4.49M | +4089.0% |
| FY2011 | Dec 31, 2011 | $107.24K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2022 | Sep 30, 2022 | $1.11M | -30.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.58M | -21.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.40M | -31.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.42M | -40.7% |
| Q3 FY2021 | Sep 30, 2021 | $1.61M | -20.8% |
| Q2 FY2021 | Jun 30, 2021 | $2.01M | -26.7% |
| Q1 FY2021 | Mar 31, 2021 | $2.05M | -37.3% |
| Q4 FY2020 | Dec 31, 2020 | $2.39M | -46.0% |
| Q3 FY2020 | Sep 30, 2020 | $2.03M | -50.3% |
| Q2 FY2020 | Jun 30, 2020 | $2.74M | -44.8% |
| Q1 FY2020 | Mar 31, 2020 | $3.27M | -48.3% |
| Q4 FY2019 | Dec 31, 2019 | $4.43M | -34.4% |
| Q3 FY2019 | Sep 30, 2019 | $4.08M | -39.2% |
| Q2 FY2019 | Jun 30, 2019 | $4.96M | -27.0% |
| Q1 FY2019 | Mar 31, 2019 | $6.32M | -10.2% |
| Q4 FY2018 | Dec 31, 2018 | $6.75M | -38.5% |
| Q3 FY2018 | Sep 30, 2018 | $6.71M | +4.2% |
| Q2 FY2018 | Jun 30, 2018 | $6.80M | -22.0% |
| Q1 FY2018 | Mar 31, 2018 | $7.04M | -8.9% |
| Q4 FY2017 | Dec 31, 2017 | $10.97M | +6.1% |
| Q3 FY2017 | Sep 30, 2017 | $6.44M | -56.1% |
| Q2 FY2017 | Jun 30, 2017 | $8.72M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.72M | – |
| Q4 FY2016 | Dec 31, 2016 | $10.34M | – |
| Q3 FY2016 | Sep 30, 2016 | $14.66M | – |
See a number that looks wrong?